Researchers continue to excited about this new drug, a groundbreaking dual agonist showing remarkable data in clinical trials for weight reduction . It acts by targeting both pathways : GLP-1 and GIP, https://dianegzuf309301.aioblogs.com/93488509/a-new-prospect-for-weight-loss